Ripple Therapeutics Announces New Vice President, Operations

TORONTO, ON, CANADA / APRIL 11, 2022 - Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel therapeutics, is pleased to announce the addition of Fraidianie Sévigné, to the leadership team as Vice President, Operations.

Fraidianie brings over 20 years of pharmaceutical industry experience, serving in senior leadership roles encompassing Operations, Quality, Compliance, and Regulatory Strategy. She has contributed to the successful launch of over 130 products, at various stages of development, from clinical evaluations to management of manufacturing scale-up and validation through to commercialization and quality operations for Canadian, U.S. and International markets.

“We are very pleased to welcome Fraidianie to Ripple as VP Operations and a member of our leadership team”, stated Tom Reeves, President and CEO, Ripple Therapeutics.  “Her vast experience in both start-up and mature pharmaceutical organizations in Operations, Quality and Regulatory Compliance will be a great complement to our existing team.  And her results-oriented leadership style and history of innovation and creativity will fit well with the Ripple culture.”

About Ripple Therapeutics

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery.  The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients.  Ripple has a full product pipeline in development.



Media Contact

Julie Fotheringham, V.P. Marketing, People & Culture

M: 416-951-7988 E: